Research Grade Anti-Human CD262/TNFRSF10B/TRAIL-R2/DR5 (LBY135)

Catalog No.

DHA29109

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG

Clonality

Monoclonal

Applications

Research Grade Biosimilar

Target

TRAILR2, TRAIL-R2, Death receptor 5, CD262, DR5, Tumor necrosis factor receptor superfamily member 10B, ZTNFR9, TRAIL receptor 2, TRICK2, TNFRSF10B, KILLER, TNF-related apoptosis-inducing ligand receptor 2

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

O14763

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

LBY135

Clone ID

LBY135

Note

For research use only. Not suitable for clinical or therapeutic use.

TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2., PMID:17922877

Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3., PMID:20884624

Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors., PMID:23589214

Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction., PMID:25484045

Inactivation of BRCA2 in human cancer cells identifies a subset of tumors with enhanced sensitivity towards death receptor-mediated apoptosis., PMID:26843614

Document Download

Research Grade Anti-Human CD262/TNFRSF10B/TRAIL-R2/DR5 (LBY135).pdf